Structure via PubChem · Public domain (PubChem)
fulvestrant
Sign in to saveAlso known as ICI 182,780
Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 410130476
- Drug.image
- Fulvestrant.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.tradename
- Faslodex, others
- Drug.MedlinePlus
- a607031
- Drug.DailyMedID
- Fulvestrant
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intramuscular injection
- Drug.class
- Antiestrogen
- Drug.ATC_prefix
- L02
- Drug.ATC_suffix
- BA03
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C32H47F5O3S
- Molecular weight
- 606.8 g/mol
- IUPAC name
- (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
- SMILES
- C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
- InChIKey
- VWUXBMIQPBEWFH-WCCTWKNTSA-N
- XLogP
- 9.2
- Polar surface area
- 76.7 Ų
- H-bond donors
- 2
- H-bond acceptors
- 9
- Formal charge
- 0
via PubChem
Research
4,385 papers- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.The Lancet. Oncology · 2016
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.Annals of oncology : official journal of the European Society for Medical Oncology · 2021
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.The New England journal of medicine · 2018
via PubMed
Wikidata facts
- Mass
- 606.3166074639998
Show 6 more facts
- defined daily dose
- 8.3
- chemical formula
- C₃₂H₄₇F₅O₃S
- isomeric SMILES
- C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
- canonical SMILES
- CC12CCC3C(C1CCC2O)C(CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
- World Health Organisation international non-proprietary name
- fulvestrant
- Commons category
- Fulvestrant
via Wikidata · CC0
~8 min read
Article
17 sectionsContents
- Medical uses
- Breast cancer
- Early puberty
- Available forms
- Contraindications
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- Society and culture
- NICE evaluation
- Patent extension
- Research
- References
Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.
Fulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.